Back
Compare AU
Compare G200 vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Wealthbuilder Aus200 Geared Complex ETF (G200) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
G200 | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 36 | 73 |
Median incremental investment | $3,017.03 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $9,344.77 | $1,658.80 |
Average age group | > 35 | > 35 |
Key Summary
G200 | CURE | |
|---|---|---|
Strategy | G200.AX was created on 2024-04-19 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. G200.AX seeks to help investors build long-term wealth by providing a cost-effective way to benefit from moderately geared exposure to the returns of the broad Australian sharemarket. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | BETASHARES AUSTRALIA 200 ETF (148.95 %) AUD - AUSTRALIA DOLLAR (-48.95 %) | Avidity Biosciences Inc Ordinary Shares (2.52 %) Revolution Medicines Inc Ordinary Shares (2.22 %) Insmed Inc (2.15 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.35 % | 0.45 % |
Key Summary
G200 | CURE | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | S&P Biotechnology Select Industry | |
Asset class | ETF | ETF |
Management fee | 0.35 % | 0.45 % |
Price | $30.79 | $57.20 |
Size | $20.849 million | $36.750 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.62 % | 5.08 % |
Market | ASX | ASX |
First listed date | 22/04/2024 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
G200 | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 36 | 73 |
Median incremental investment | $3,017.03 | $660.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $9,344.77 | $1,658.80 |
Average age group | > 35 | > 35 |
Pros and Cons
G200 | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
G200 | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |